Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5759177 | 1.00 | KIF11 (0.54) | KIF11TDP1EGFRCYP3A4MAP1LC3B | |
| SCHEMBL5649781 | 0.89 | TDP1 (0.51) | KIF11TDP1EGFRCYP3A4MAP1LC3B | |
| SCHEMBL5647619 | 0.89 | TDP1 (0.55) | KIF11TDP1EGFRCYP3A4MAP1LC3B | |
| SCHEMBL5753899 | 0.83 | KIF11 (0.46) | KIF11TDP1EGFRCYP3A4MAP1LC3B | |
| SCHEMBL5753869 | 0.83 | KIF11 (0.47) | KIF11TDP1EGFRCYP3A4MAP1LC3B | |
| SCHEMBL5489358 | 0.83 | PDE4A (0.48) | TDP1CYP3A4CYP2C19PDE4APDE4B | |
| SCHEMBL5604903 | 0.81 | KIF11 (0.67) | KIF11TDP1EGFRCYP3A4MAP1LC3B | |
| SCHEMBL4620734 | 0.80 | KIF11 (0.57) | KIF11TDP1EGFRCYP3A4MAP1LC3B | |
| SCHEMBL5755084 | 0.80 | PTGS1 (0.49) | KIF11TDP1EGFRCYP3A4MAP1LC3B | |
| SCHEMBL5751626 | 0.79 | KIF11 (0.51) | KIF11TDP1EGFRCYP3A4MAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1855685-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-7161002-B2 | Syntheses of quinazolinones | CYTOKINETICS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1553931-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006078598-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-7009049-B2 | Syntheses of quinazolinones | CYTOKINETICS, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-20060041130-A1 | Syntheses of quinazolinones | CYTOKINETICS, INC. AND SMITHKLINE BEECHAM CORP. | 2006-02-23 | — | — | US | disclosed |
| EP-1553931-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1480980-A4 | SYNTHESES OF QUINAZOLINONES | CYTOKINETICS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1480980-A2 | SYNTHESES OF QUINAZOLINONES | Cytokinetics, Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040067969-A1 | Syntheses of quinazolinones | CYTOKINETICS, INCORPORATED | 2004-04-08 | — | — | US | disclosed |
| WO-2003097053-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003070701-A2 | SYNTHESES OF QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067969-A1 | Syntheses of quinazolinones | NDUFS3, NDUFS2, NQO2 | KIF11 1865/4885TDP1 1325/4885EGFR 4538/4885 |
| US-20060041130-A1 | Syntheses of quinazolinones | NDUFS3, NDUFS2, NQO2 | KIF11 1865/4885TDP1 1325/4885EGFR 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.